Slingshot members are tracking this event:
Regeneron (REGN) and Sanofi (SNY) Announce Positive Dupixent (dupilumab) Phase 3 Atopic Dermatitis Data Published in the New England Journal of Medicine
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Oct 01, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Dupixent, Dupilumab, Atopic Dermatitis